Pharvaris Announces Annual Meeting of Shareholders
June 01 2023 - 5:50AM
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing
novel, oral bradykinin-B2-receptor antagonists to treat and prevent
hereditary angioedema (HAE) attacks, today announced the annual
general meeting of shareholders will take place on Friday, June 23,
2023, at 15:00 CEST (9:00 a.m. EDT).
All relevant documents and information relating to the annual
general meeting, including the notice and agenda for the annual
general meeting, are or will be made available in the “Investors”
section of Pharvaris’ website under “Events & Presentations”.
The documents will also be made available on the SEC’s website
at www.sec.gov. Shareholders who wish to attend the meeting
should register as described in the notice and agenda for the
annual general meeting.
About PharvarisBuilding on its deep-seated
roots in hereditary angioedema (HAE), Pharvaris is a clinical-stage
company developing novel, oral bradykinin-B2-receptor antagonists
to treat and prevent HAE attacks. By directly targeting this
clinically proven therapeutic target with novel small molecules,
the Pharvaris team aspires to offer people with all sub-types of
HAE safe, effective, and convenient alternatives to treat attacks,
both on-demand and prophylactically. The company brings together
the best talent in the industry with deep expertise in rare
diseases and HAE. For more information, visit
https://pharvaris.com/
Contact
Maggie Beller
Head of Public Relations and Communications
maggie.beller@pharvaris.com
Pharvaris NV (NASDAQ:PHVS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Pharvaris NV (NASDAQ:PHVS)
Historical Stock Chart
From Jul 2023 to Jul 2024